Dr Reddys commissions mPEG alcohol manufacturing facility
Dedicated facility will operate to c-GMP standards
The new facility is capable of producing a wide range of molecular weight mPEGs and has a multitonne annual capacity. The mPEG alcohol manufactured in Mexico will be supplied to Dr. Reddy’s c-GMP facility in Mirfield, UK, where commercial scale activation is carried out.
mPEG alcohols are the key raw materials for Activated mPEG, extensively used for pegylation with biologic drugs and increasingly for peptides and small molecule pharmaceuticals. Dr. Reddy’s has officially branded its extensive range of Activated mPEGs under the name PEGtech.
PEGtech branding has been used to bring together a broad product range comprising a variety of activating groups and molecular weights (5-60 kDa), which are now fully supported by backward integration to the key starting materials. It furthermore highlights the company’s extensive experience in product development and GMP manufacture of the Activated mPEGs.
‘Our investment in the world class mPEG alcohol facility in Mexico underlines our commitment to the growing market for Activated mPEGs,’ said Satish Reddy, managing director and coo, Dr. Reddy’s, ‘By introducing the PEGtech brand, our customers can be assured of the same high quality standards and customer service as they develop their PEGylated biologic drugs or small molecules from the laboratory right through to commercial applications.’
You may also like
Manufacturing
Cellevate achieves ISO 9001:2015 certification alongside GMP production processes in new cleanroom
Read moreThe certification caps off a strong 2025 for the company, which now has a scalable foundation for expanding manufacturing capacity and implementing GMP-ready processes for commercial volumes
Trending Articles
You may also like
Manufacturing
Cellevate achieves ISO 9001:2015 certification alongside GMP production processes in new cleanroom
The certification caps off a strong 2025 for the company, which now has a scalable foundation for expanding manufacturing capacity and implementing GMP-ready processes for commercial volumes
Manufacturing
LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener
Following the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying applications, Dr Kevin Robinson caught up with Senior Director of Lyophilization Technology Management, Thomas Beutler, to find out more
Manufacturing
Particology joins £8.2m consortium to drive greener, more efficient medicines manufacturing
The company has been selected for Innovate UK’s £54m Sustainable Medicines Manufacturing Innovation Programme, leading crystallisation research to cut waste, reduce energy use and accelerate next-generation pharmaceutical production
Manufacturing
Valve diagnostics: providing new insights for medical and lab applications
Across a range of medical and laboratory applications, confirmation of liquid flow status is critical, but integrating sensors or electronics to check the performance of functions like valve switching adds design complexity
Manufacturing
Marchesini Group and AST announce strategic partnership to strengthen aseptic production capacity and expand global market presence
Marchesini Group, a leader in pharmaceutical packaging machinery, and AST, a US leader in the drug product manufacturing industry, have entered a strategic partnership that combines the expertise, technologies, and global reach of two highly respected industry leaders